• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Phio Pharmaceuticals Corp. - Common Stock (NQ:PHIO)

    1.205 +0.015 (+1.26%)
    Streaming Delayed Price Updated: 2:05 PM EDT, Apr 27, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 64,856
    Open 1.180
    Bid (Size) 1.200 (300)
    Ask (Size) 1.210 (2,600)
    Prev. Close 1.190
    Today's Range 1.180 - 1.220
    52wk Range 0.8127 - 4.190
    Shares Outstanding 5,726,750
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
    King of Prussia, Pennsylvania--(Newsfile Corp. - April 23, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical... 
    Via Newsfile
    News headline image
    Phio Pharmaceuticals Announces "Nobel Prize Winning Science Takes on Skin Cancer" in a Fireside Chat with Force Family Office on Wednesday, April 15, 2026
    Phio invites investors, advisors and analysts with an interest in the life sciences sector to attend this virtual eventR.... 
    Via Newsfile

    Performance

    YTD
    +10.6%
    +10.6%
    1 Month
    -4.4%
    -4.4%
    3 Month
    +15.9%
    +15.9%
    6 Month
    -44.3%
    -44.3%
    1 Year
    -43.7%
    -43.7%

    More News

    Read More
    News headline image
    Phio Pharmaceuticals Announces Presentation at Centri Capital Conference on April 14, 2026
    Via Newsfile
    News headline image
    Phio Pharmaceuticals Announces Agreement with U.S. cGMP Manufacturing Source for Drug Product, PH-762
    Via Newsfile
    News headline image
    Phio Pharmaceuticals Announces American Academy of Dermatology 2026 Presentation Featuring Clinical Study Results from Study of PH-762 for Cutaneous Carcinoma Underscoring Clinical Pipeline Advancement
    Via Newsfile
    News headline image
    Phio Pharmaceuticals Announces "A Groundbreaking Approach to Treating Skin Cancer" in a Fireside Chat with Force Family Office
    Via Newsfile
    News headline image
    Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing
    From Virtual Investor Conferences
    Via GlobeNewswire
    News headline image
    Life Sciences Virtual Investor Forum Agenda Announced for March 11th & 12th
    From Virtual Investor Conferences
    Via GlobeNewswire
    News headline image
    Phio Pharmaceuticals to Present at the Life Sciences Investor Forum on March 12, 2026 11 AM EDT
    From Virtual Investor Conferences
    Via GlobeNewswire
    News headline image
    Phio Pharmaceuticals to Present at the Life Sciences Investor Forum on March 12, 2026, 11 AM EDT
    Via Newsfile
    News headline image
    Phio Pharmaceuticals Reports 2025 Year-End Financial Results and Business Update
    Via Newsfile
    News headline image
    Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
    Via Newsfile
    News headline image
    Phio Pharmaceuticals Corp. Selected as B2i Digital Featured Company
    Via TheNewswire.com
    News headline image
    Phio Pharmaceuticals Corp. Selected as B2i Digital Featured Company
    Via NewMediaWire
    News headline image
    Phio Pharmaceuticals Aligns Leadership Team to Support Next Stage Development of PH-762 and Advancement of PH-894
    Via Newsfile
    Topics Initial Public Offering
    Here are the top movers in Wednesday's session. ↗
    Via Chartmill
    Top movers in Wednesday's session ↗
    Via Chartmill
    Let's have a look at the top gainers and losers one hour before the close of the markets of today's session. ↗
    Via Chartmill
    The trading volume of these stocks is deviating from the norm in today's session. ↗
    Via Chartmill
    On Wednesday, there are stocks with unusual volume. Let's take a look. ↗
    Via Chartmill
    Top stock movements in today's session. ↗
    Via Chartmill
    These stocks are making the most noise in today's session. ↗
    Via Chartmill
    Here are the top movers in Tuesday's session. ↗
    Via Chartmill
    These stocks are gapping in today's session ↗
    Via Chartmill
    Top movers in Tuesday's pre-market session ↗
    Via Chartmill

    Frequently Asked Questions

    Is Phio Pharmaceuticals Corp. - Common Stock publicly traded?
    Yes, Phio Pharmaceuticals Corp. - Common Stock is publicly traded.
    What exchange does Phio Pharmaceuticals Corp. - Common Stock trade on?
    Phio Pharmaceuticals Corp. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Phio Pharmaceuticals Corp. - Common Stock?
    The ticker symbol for Phio Pharmaceuticals Corp. - Common Stock is PHIO on the Nasdaq Stock Market
    What is the current price of Phio Pharmaceuticals Corp. - Common Stock?
    The current price of Phio Pharmaceuticals Corp. - Common Stock is 1.205
    When was Phio Pharmaceuticals Corp. - Common Stock last traded?
    The last trade of Phio Pharmaceuticals Corp. - Common Stock was at 04/27/26 02:05 PM ET
    What is the market capitalization of Phio Pharmaceuticals Corp. - Common Stock?
    The market capitalization of Phio Pharmaceuticals Corp. - Common Stock is 6.90M
    How many shares of Phio Pharmaceuticals Corp. - Common Stock are outstanding?
    Phio Pharmaceuticals Corp. - Common Stock has 7M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.